Form 8-K

8-K — Cryoport, Inc.

Accession: 0001104659-26-092064

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0001124524

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2622464d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622464d1_ex99-1.htm)

GRAPHIC (tm2622464d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622464d1_8k.htm · Sequence: 1

false

0001124524

2026-08-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported): August 6, 2026

CRYOPORT, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-34632

88-0313393

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

112

Westwood Place, Suite

350, Brentwood,

TN 37027

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (949) 470-2300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section

12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which

registered

Common Stock, $0.001 par value

CYRX

The NASDAQ Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, Cryoport, Inc. (the

“Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy

of the press release issued by the Company is attached hereto as Exhibit 99.1.

The information, including the exhibit attached

hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall

it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly

stated in such filing.

Item 9.01.

Financial Statements and Exhibits

(d)

Exhibits.

The following material is filed as an exhibit to this Current Report on Form 8-K:

Exhibit

Number

99.1 Press

Release dated August 6, 2026 issued by the Company.

104 Cover

Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 6, 2026

Cryoport, Inc.

/s/ Robert Stefanovich

Robert Stefanovich

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622464d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Cryoport Reports Second Quarter

2026 Financial Results

· Second quarter revenue

grew 8% year-over-year to $49.0 million

· Life Sciences Services

revenue increased 15% year-over-year

· BioStorage/BioServices

revenue grew 25% year-over-year

· Supporting 779 global

clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026

NASHVILLE,

Tennessee, August 6, 2026, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”

or the “Company”), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences,

today announced financial results for its second quarter (Q2) and first half (H1) of 2026.

Jerrell

Shelton, CEO of Cryoport, commented, “Our revenue momentum over the past several periods continued into the second quarter, with

total revenue reaching $49.0 million. Life Sciences Services revenue grew 15% year-over-year, led by 25% growth in BioStorage/BioServices

revenue. Our Life Sciences Products business also generated solid results during the quarter, driven by continued demand for MVE Biological

Solutions’ industry-leading cryogenic systems and the successful introduction of new and innovative products.

“Total

revenue from the support of commercial CGT grew 9% year-over-year to $9.4 million. The Life Science Services portion of our revenue from

supporting commercial CGT grew 26% year-over-year as the number of patients treated in the community setting and on an outpatient basis

continued to ramp. Total revenue for the quarter from supporting CGT clinical trials increased 12% year-over-year to $13.4 million as

our customers’ clinical pipelines advanced and further matured. We supported a record 779 clinical trials globally as of June 30,

2026, reflecting the strength of our industry-leading position as the CGT market continues to advance.

“Our

second quarter results also reflect meaningful progress on our “pathway to profitability.” Achieving positive adjusted EBITDA

in the second quarter represents an important milestone in our ongoing pathway to sustainable profitability and demonstrates the value

of our strategic investments and operational initiatives we have executed over the past several years. We are pleased with this accomplishment

as we continue to optimize our global operations, leverage our expanding infrastructure, and benefit from the operating leverage that

we anticipate will take effect as we increasingly scale and put our investments to work.

“Overall, we delivered a strong

second quarter, generating growth across key revenue streams, improving profitability, and achieving an important milestone with positive

adjusted EBITDA for the quarter. With our accomplishments to date, we believe that we are well positioned to further expand margins, enhance

operating efficiency, and deliver sustainable, profitable long-term growth for our shareholders. We remain focused on executing our strategy,

driving financial performance, and capitalizing on the significant opportunities before us. We expect upcoming growth catalysts in our

business segments, represented by the expansion of our Global Supply Chain Center Network and recent launches of new products and services,

will drive us to new heights in market position, growth, and productivity,” concluded Mr. Shelton.

The following table presents Q2 2026 revenue compared with

Q2 2025:

Cryoport, Inc. and Subsidiaries

Revenue

Three Months Ended

June 30,

(unaudited)

Six Months Ended

June 30,

(unaudited)

(in thousands)

2026

2025

% Change

2026

2025

% Change

Life Sciences Services

$ 27,969

$ 24,369

15 %

$ 54,867

$ 47,234

16 %

BioLogistics Solutions

22,359

19,874

13 %

44,027

38,404

15 %

BioStorage/BioServices

5,610

4,495

25 %

10,840

8,830

23 %

Life Sciences Products

$ 21,002

$ 21,085

0 %

$ 41,902

$ 39,260

7 %

Total Revenue

$ 48,971

$ 45,454

8 %

$ 96,769

$ 86,494

12 %

BioLogistics Solutions revenue increased

13% year-over-year in Q2 2026, driven by increasing customer activity, continued commercial product development, and clinical advancement

within the CGT market. BioStorage/BioServices revenue grew 25% year-over-year, reflecting strong demand for our expanded, integrated services

offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.

As of June 30, 2026, the number

of commercial cell and gene therapies we support increased to 22 and our total clinical trial count that we support rose to 779 clinical

trials worldwide, a net increase of 51 clinical trials over June 30, 2025, with 94 of these clinical trials in Phase 3. The number

of trials by phase and region are as follows:

Cryoport Supported Clinical Trials by Phase

June 30,

Clinical Trials

2024

2025

2026

Phase 1

286

304

316

Phase 2

322

342

369

Phase 3

Total

684

728

779

Cryoport Supported Clinical Trials by Region

June 30,

Clinical Trials

2024

2025

2026

Americas

525

556

579

EMEA

114

124

145

APAC

Total

684

728

779

In Q2 2026, four of our customers filed

Biologics License Applications (BLA) / Marketing Authorization Applications (MAA). During the Q2 2026, Cryoport’s customer, Orca

Bio, received U.S. Food and Drug Administration (FDA) approval for TREGZI™ as the first and only precision-engineered cell therapy

for allogeneic stem cell transplant in the treatment of adults with hematological malignancies. Additionally, during Q2 2026, Vertex Pharmaceuticals

received supplemental approval from the FDA to expand the label of CASGEVY® for the treatment of patients aged two years

and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia

(TDT). CASGEVY is the first approved gene therapy indicated for children as young as two years for both SCD and TDT. For the balance of

2026, we anticipate another 11 possible BLA/MAA applications, five possible additional new therapy approvals, and one possible additional

approval for label/geographic expansion from our customer base.

Operational milestones

· Cryoport Systems' IntegriCell®

cryopreservation services were selected by Verismo Therapeutics, a clinical-stage CAR T-cell therapy company pioneering a novel multi-chain

KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310).

· Advanced toward the planned launch of BioServices

operations at our Global Supply Chain Center in Paris, France, expected in Q4 2026.

· Continued progress toward the launch of our

state-of-the-art Global Supply Chain Center in Santa Ana, California, expected in Q4 2026.

· Shipped first HE freezers “made in China

for China” from our Chengdu, China manufacturing facility.

Financial

Highlights

On June 11, 2025, the Company

completed the divestiture of its CRYOPDP specialty courier business to DHL Group. The results of CRYOPDP, a former business within Cryoport’s

Life Sciences Services segment, are presented as discontinued operations for all periods and are excluded from the non-GAAP financial

measures in this release.

Revenue

· Total revenue for Q2 2026 was $49.0 million, compared to $45.5 million

for Q2 2025, a year-over-year increase of 8%, or $3.5 million.

o Life Sciences Services revenue for Q2 2026 (representing 57% of our total revenue) was $28.0 million, compared to $24.4 million

for Q2 2025, up 15% year-over-year, including BioStorage/BioServices revenue of $5.6 million, up 25% year-over-year.

o Life Sciences Products revenue for Q2 2026 (representing 43% of our total revenue) was $21.0 million, compared to $21.1 million

for Q2 2025.

· Total revenue for H1 2026 was $96.8 million, compared to $86.5 million

for H1 2025.

o Life Sciences Services revenue for H1 2026 was $54.9 million, compared to $47.2 million for H1 2025, including BioStorage/BioServices

revenue of $10.8 million, compared to $8.8 million for H1 2025.

o Life Sciences Products revenue for H1 2026 was $41.9 million, compared to $39.3 million for H1 2025.

Gross Margin

· Total gross margin was 46.6% for Q2 2026, compared to 47.0% for Q2 2025.

o Gross margin for Life Sciences Services was 49.9% for Q2 2026, compared to 48.9% for Q2 2025.

o Gross margin for Life Sciences Products was 42.2% for Q2 2026, compared to 44.9% for Q2 2025.

· Total gross margin was 46.2% for H1 2026, compared to 46.3% for H1 2025.

o Gross margin for Life Sciences Services was 49.4% for H1 2026, compared to 48.4% for H1 2025.

o Gross margin for Life Sciences Products was 42.1% for H1 2026, compared to 43.7% for H1 2025.

Operating Costs and Expenses

· Operating costs and expenses were $32.9 million

for Q2 2026, compared to $31.0 million for Q2 2025. Operating costs and expenses were $64.4 million for H1 2026, compared to $56.9 million

for H1 2025.

Loss from Continuing Operations

· Loss from continuing operations was $8.3 million

for Q2 2026, compared to a loss of $12.0 million for Q2 2025. Loss from continuing operations was $17.7 million for H1 2026, compared

to a loss of $18.8 million for H1 2025.

Net Income (Loss) – including

Discontinued Operations

· Net loss was $8.3 million for Q2 2026, compared

to net income of $108.9 million for Q2 2025. Net loss for H1 2026 was $18.8 million, compared to net income of $96.9 million for H1 2025.

Net income for Q2 2025 and H1 2025 was primarily driven by the sale of our CRYOPDP specialty courier business during Q2 2025, which contributed

$120.9 million and $115.6 million, net of taxes, respectively, to income from discontinued operations.

· Net loss attributable to common stockholders

for Q2 2026 was $10.3 million, or $0.20 per share. Net loss attributable to common stockholders for H1 2026 was $22.8 million, or $0.45

per share. This compares to net income attributable to common stockholders of $106.9 million, or $2.13 per share, and $92.9 million, or

$1.85 per share, for Q2 2025 and H1 2025, respectively.

Adjusted EBITDA from Continuing

Operations

· Adjusted EBITDA from continuing operations

was $0.4 million for Q2 2026, compared to a negative $0.9 million for Q2 2025. Adjusted EBITDA from continuing operations for H1 2026

was a negative $0.2 million, compared to a negative $3.7 million for H1 2025.

Cash, Cash equivalents, and Short-Term

Investments

· Cryoport held $396.7 million in cash, cash

equivalents, and short-term investments as of June 30, 2026.

Note: All reconciliations

of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.

Additional Information

Further information on Cryoport’s financial

results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of

Cryoport’s financial performance are provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30,

2026, which is expected to be filed with the Securities and Exchange Commission ("SEC") on August 6, 2026. Additionally,

the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport’s website at www.cryoportinc.com.

Earnings Conference Call Information

IMPORTANT INFORMATION: In addition to

the earnings release, a document titled “Cryoport Second Quarter 2026 in Review,” providing a review of Cryoport’s

business update, will be issued at 4:05 p.m. ET on Thursday, August 6, 2026. The document is designed to be read in advance

of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.

Cryoport management will host a conference

call at 5:00 p.m. ET on August 6, 2026. The conference call will be in the format of a questions and answers session and will

address any queries investors have regarding the Company’s reported results. A slide deck will accompany the call.

Conference Call Information

Date:

Thursday, August 6, 2026

Time:

5:00 p.m. ET

Dial-in numbers:

1-800-717-1738 (U.S.), 1-646-307-1865 (International)

Confirmation code:

Request the “Cryoport Call” or Conference ID: 1142151

Live webcast:

‘Investor Relations’ section

at www.cryoportinc.com or click here.

Please allow 10 minutes prior to the

call to visit this site to download and install any necessary audio software.

The questions and answers call will be recorded

and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website

at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay

of the call will also be available to those interested, until August 13, 2026. To access the replay, dial 1-844-512-2921 (United

States) or 1-412-317-6671 (International) and enter replay entry code: 1142151#.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX) is

a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative

medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers,

and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled

supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management

Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation

services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life

sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."

Headquartered in Nashville, Tennessee,

our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com

or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport

for live updates.

Forward-Looking Statements

Statements in this press release which

are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections,

plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act

of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term

growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and

guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the

markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as

the expected timing and benefits of such products and services launches, the Company’s expectations about future benefits of its

acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved

with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company’s plans

regarding its Global Supply Chain Centers, including expected timing of future openings, the Company’s anticipation that it will

benefit from its operating leverage, the Company’s belief that it is well positioned to further expand margins, enhance operating

efficiency and deliver sustainable, profitable long-term growth for its shareholders, and the Company’s expectation that upcoming

growth catalysts in its business segments will drive the Company to new heights in market position, growth, and productivity. It is important

to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could

cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing

economic and geopolitical conditions, such as those resulting from the war with Iran, supply chain constraints, inflationary pressures,

the effects of foreign currency fluctuations, trends in the products markets, variations in the Company’s cash flow, market acceptance

risks, the effects of tariffs and other trade restrictions, and technical development risks. The Company's business could be affected

by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed

periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements

contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these

forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise

any forward-looking statements in this press release.

Cryoport Investor Contacts:

Todd Fromer / Scott Eckstein

KCSA Strategic Communications

cryoport@kcsa.com

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

Three Months Ended

June 30,

(unaudited)

Six Months Ended

June 30,

(unaudited)

(in thousands, except share and per share data)

2026

2025

2026

2025

Revenue

Life Sciences Services revenue

$ 27,969

$ 24,369

$ 54,867

$ 47,234

Life Sciences Products revenue

21,002

21,085

41,902

39,260

Total revenue

48,971

45,454

96,769

86,494

Cost of revenue:

Cost of services revenue

14,008

12,449

27,755

24,369

Cost of products revenue

12,139

11,628

24,277

22,107

Total cost of revenue

26,147

24,077

52,032

46,476

Gross margin

22,824

21,377

44,737

40,018

Operating costs and expenses:

Selling, general and administrative

28,011

26,908

55,631

48,809

Engineering and development

4,852

4,118

8,759

8,052

Total operating costs and expenses:

32,863

31,026

64,390

56,861

Loss from operations

(10,039 )

(9,649 )

(19,653 )

(16,843 )

Other income (expense):

Investment income

3,132

1,466

6,222

3,039

Interest expense

(518 )

(618 )

(950 )

(1,201 )

Other expense, net

(325 )

(2,939 )

(2,693 )

(3,239 )

Loss before provision for income taxes

(7,750 )

(11,740 )

(17,074 )

(18,244 )

Provision for income taxes

(505 )

(274 )

(613 )

(508 )

Loss from continuing operations

$ (8,255 )

$ (12,014 )

$ (17,687 )

$ (18,752 )

Income (loss) from discontinued operations, net

120,883

(1,112 )

115,640

Net income (loss)

$ (8,255 )

$ 108,869

$ (18,799 )

$ 96,888

Paid-in-kind dividend on Series C convertible preferred stock

(2,000 )

(4,000 )

Net income (loss) attributable to common stockholders

$ (10,255 )

$ 106,869

$ (22,799 )

$ 92,888

Net income (loss) per share attributable to common stockholders - basic and diluted

$ (0.20 )

$ 2.13

$ (0.45 )

$ 1.85

Weighted average common shares issued and outstanding - basic and diluted

50,442,796

50,257,112

50,173,730

50,102,918

Gross margin - Total [%]

46.6 %

47.0 %

46.2 %

46.3 %

Gross margin - Services [%]

49.9 %

48.9 %

49.4 %

48.4 %

Gross margin - Products [%]

42.2 %

44.9 %

42.1 %

43.7 %

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

June 30,

December 31,

2026

2025

(in thousands)

(unaudited)

Current assets

Cash and cash equivalents

$ 269,267

$ 250,494

Short-term investments

127,426

160,714

Accounts receivable, net

36,454

33,359

Inventories

21,506

23,188

Prepaid expenses and other current assets

5,550

8,419

Total current assets

460,203

476,174

Property and equipment, net

94,516

85,448

Operating lease right-of-use assets

40,323

39,720

Intangible assets, net

135,992

138,082

Goodwill

22,068

22,400

Deposits

2,038

2,092

Deferred tax assets

1,064

1,073

Total assets

$ 756,204

$ 764,989

Current liabilities

Accounts payable and other accrued expenses

$ 16,247

$ 15,283

Accrued compensation and related expenses

12,186

12,980

Deferred revenue

1,720

943

Current portion of operating lease liabilities

3,937

4,133

Current portion of finance lease liabilities

448

422

Current portion of convertible senior notes, net

185,687

185,094

Current portion of notes payable

159

163

Current portion of contingent consideration

652

Total current liabilities

221,036

219,018

Notes payable, net

985

1,087

Operating lease liabilities, net

40,076

39,078

Finance lease liabilities, net

726

741

Deferred tax liabilities

1,850

1,354

Other long-term liabilities

832

444

Contingent consideration

629

Total liabilities

265,505

262,351

Total stockholders' equity

490,699

502,638

Total liabilities and stockholders' equity

$ 756,204

$ 764,989

Note Regarding Use of Non-GAAP Financial Measures

To supplement our financial statements, which

are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measure of financial performance

as defined in Regulation G of the Securities Exchange Act of 1934 is included in this release: adjusted EBITDA from continuing operations.

Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or

principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including

adjusted EBITDA from continuing operations, should not be considered as a substitute for, or superior to, measures of financial performance

prepared in accordance with GAAP.

Adjusted EBITDA from continuing operations is

defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based

compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized (gain)/loss on investments,

foreign currency loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as

applicable.

Management believes that adjusted EBITDA from

continuing operations provides a useful measure of Cryoport's operating results, a meaningful comparison with historical results and with

the results of other companies, and insight into Cryoport's ongoing operating performance. Further, management and the Company’s

board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport's comparative operating

performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA from continuing operations

is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes

adjusted EBITDA from continuing operations, when read in conjunction with Cryoport's GAAP financials, is useful to investors because it

provides a basis for meaningful period-to-period comparisons of Cryoport's ongoing operating results, including results of operations,

against investor and analyst financial models, helps identify trends in Cryoport's underlying business and in performing related trend

analyses, and it provides a better understanding of how management plans and measures Cryoport's underlying business.

Cryoport, Inc. and Subsidiaries

Reconciliation of GAAP loss from continuing operations to adjusted EBITDA

(unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

(in thousands)

2026

2025

2026

2025

GAAP loss from continuing operations

$ (8,255 )

$ (12,014 )

$ (17,687 )

$ (18,752 )

Non-GAAP adjustments to loss:

Depreciation and amortization expense

6,589

6,249

12,991

12,383

Acquisition and integration costs

—

Cost reduction initiatives

140

266

140

482

Investment income

(3,132 )

(1,466 )

(6,222 )

(3,039 )

Unrealized (gain) loss on investments

(212 )

1,082

1,893

1,275

Foreign currency loss

651

2,002

1,105

2,247

Interest expense, net

518

618

950

1,201

Stock-based compensation expense

2,402

2,045

4,797

5,109

Change in fair value of contingent consideration

—

(5,178 )

Income taxes

505

274

613

508

Other adjustments

1,142

—

1,142

—

Adjusted EBITDA from continuing operations

$ 375

$ (914 )

$ (236 )

$ (3,733 )

GRAPHIC

Filename: tm2622464d1_ex99-1img001.jpg · Sequence: 6

Binary file (8750 bytes)

Download tm2622464d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 06, 2026

Entity File Number

001-34632

Entity Registrant Name

CRYOPORT, INC.

Entity Central Index Key

0001124524

Entity Tax Identification Number

88-0313393

Entity Incorporation, State or Country Code

Entity Address, Address Line One

112

Westwood Place

Entity Address, Address Line Two

Suite

350

Entity Address, City or Town

Brentwood

Entity Address, State or Province

Entity Address, Postal Zip Code

37027

City Area Code

949

Local Phone Number

470-2300

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

CYRX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration